Global Antibody and Recombinant Protein CDMO Market Research Report 2023(Status and Outlook)
- Published Date: 2023-08-20
- Report ID: 145835
- Pages: 250
-
Format:
Report Overview
Prudent Markets latest report provides a deep insight into the global Antibody and Recombinant Protein CDMO market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porters five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Antibody and Recombinant Protein CDMO Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Antibody and Recombinant Protein CDMO market in any manner.
Global Antibody and Recombinant Protein CDMO Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Batavia Biosciences
Grifols
Cerbios-Pharma SA
HALIX
Biovian Oy
Catalent
Goodwin Biotechnology
Merck
Hangzhou Hs-biopharm
Wuxibiologics
Bioinnobio
Thousand Oaks Biopharmaceuticals
Cerbios-Pharma SA
Eurogentec
HJB
Bibo Pharma
MabPlex International
Genscriptprobio
Vetter
Etinpro (Beijing) Co
Boehringer Ingelheim BioXcellence
Lonza
3SBio Inc
Porton
Market Segmentation (by Type)
Antibody CDMO
Recombinant Protein CDMO
Market Segmentation (by Application)
Pharmaceutical Company
Biotechnology Company
Generic Company
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Antibody and Recombinant Protein CDMO Market
Overview of the regional outlook of the Antibody and Recombinant Protein CDMO Market:
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value (USD Billion) data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porters five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Antibody and Recombinant Protein CDMO Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Antibody and Recombinant Protein CDMO
1.2 Key Market Segments
1.2.1 Antibody and Recombinant Protein CDMO Segment by Type
1.2.2 Antibody and Recombinant Protein CDMO Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Antibody and Recombinant Protein CDMO Market Overview
2.1 Global Market Overview
2.1.1 Global Antibody and Recombinant Protein CDMO Market Size (M USD) Estimates and Forecasts (2018-2029)
2.1.2 Global Antibody and Recombinant Protein CDMO Sales Estimates and Forecasts (2018-2029)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Antibody and Recombinant Protein CDMO Market Competitive Landscape
3.1 Global Antibody and Recombinant Protein CDMO Sales by Manufacturers (2018-2023)
3.2 Global Antibody and Recombinant Protein CDMO Revenue Market Share by Manufacturers (2018-2023)
3.3 Antibody and Recombinant Protein CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Antibody and Recombinant Protein CDMO Average Price by Manufacturers (2018-2023)
3.5 Manufacturers Antibody and Recombinant Protein CDMO Sales Sites, Area Served, Product Type
3.6 Antibody and Recombinant Protein CDMO Market Competitive Situation and Trends
3.6.1 Antibody and Recombinant Protein CDMO Market Concentration Rate
3.6.2 Global 5 and 10 Largest Antibody and Recombinant Protein CDMO Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Antibody and Recombinant Protein CDMO Industry Chain Analysis
4.1 Antibody and Recombinant Protein CDMO Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Antibody and Recombinant Protein CDMO Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Antibody and Recombinant Protein CDMO Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Antibody and Recombinant Protein CDMO Sales Market Share by Type (2018-2023)
6.3 Global Antibody and Recombinant Protein CDMO Market Size Market Share by Type (2018-2023)
6.4 Global Antibody and Recombinant Protein CDMO Price by Type (2018-2023)
7 Antibody and Recombinant Protein CDMO Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Antibody and Recombinant Protein CDMO Market Sales by Application (2018-2023)
7.3 Global Antibody and Recombinant Protein CDMO Market Size (M USD) by Application (2018-2023)
7.4 Global Antibody and Recombinant Protein CDMO Sales Growth Rate by Application (2018-2023)
8 Antibody and Recombinant Protein CDMO Market Segmentation by Region
8.1 Global Antibody and Recombinant Protein CDMO Sales by Region
8.1.1 Global Antibody and Recombinant Protein CDMO Sales by Region
8.1.2 Global Antibody and Recombinant Protein CDMO Sales Market Share by Region
8.2 North America
8.2.1 North America Antibody and Recombinant Protein CDMO Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Antibody and Recombinant Protein CDMO Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Antibody and Recombinant Protein CDMO Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Antibody and Recombinant Protein CDMO Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Antibody and Recombinant Protein CDMO Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Batavia Biosciences
9.1.1 Batavia Biosciences Antibody and Recombinant Protein CDMO Basic Information
9.1.2 Batavia Biosciences Antibody and Recombinant Protein CDMO Product Overview
9.1.3 Batavia Biosciences Antibody and Recombinant Protein CDMO Product Market Performance
9.1.4 Batavia Biosciences Business Overview
9.1.5 Batavia Biosciences Antibody and Recombinant Protein CDMO SWOT Analysis
9.1.6 Batavia Biosciences Recent Developments
9.2 Grifols
9.2.1 Grifols Antibody and Recombinant Protein CDMO Basic Information
9.2.2 Grifols Antibody and Recombinant Protein CDMO Product Overview
9.2.3 Grifols Antibody and Recombinant Protein CDMO Product Market Performance
9.2.4 Grifols Business Overview
9.2.5 Grifols Antibody and Recombinant Protein CDMO SWOT Analysis
9.2.6 Grifols Recent Developments
9.3 Cerbios-Pharma SA
9.3.1 Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Basic Information
9.3.2 Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Product Overview
9.3.3 Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Product Market Performance
9.3.4 Cerbios-Pharma SA Business Overview
9.3.5 Cerbios-Pharma SA Antibody and Recombinant Protein CDMO SWOT Analysis
9.3.6 Cerbios-Pharma SA Recent Developments
9.4 HALIX
9.4.1 HALIX Antibody and Recombinant Protein CDMO Basic Information
9.4.2 HALIX Antibody and Recombinant Protein CDMO Product Overview
9.4.3 HALIX Antibody and Recombinant Protein CDMO Product Market Performance
9.4.4 HALIX Business Overview
9.4.5 HALIX Antibody and Recombinant Protein CDMO SWOT Analysis
9.4.6 HALIX Recent Developments
9.5 Biovian Oy
9.5.1 Biovian Oy Antibody and Recombinant Protein CDMO Basic Information
9.5.2 Biovian Oy Antibody and Recombinant Protein CDMO Product Overview
9.5.3 Biovian Oy Antibody and Recombinant Protein CDMO Product Market Performance
9.5.4 Biovian Oy Business Overview
9.5.5 Biovian Oy Antibody and Recombinant Protein CDMO SWOT Analysis
9.5.6 Biovian Oy Recent Developments
9.6 Catalent
9.6.1 Catalent Antibody and Recombinant Protein CDMO Basic Information
9.6.2 Catalent Antibody and Recombinant Protein CDMO Product Overview
9.6.3 Catalent Antibody and Recombinant Protein CDMO Product Market Performance
9.6.4 Catalent Business Overview
9.6.5 Catalent Recent Developments
9.7 Goodwin Biotechnology
9.7.1 Goodwin Biotechnology Antibody and Recombinant Protein CDMO Basic Information
9.7.2 Goodwin Biotechnology Antibody and Recombinant Protein CDMO Product Overview
9.7.3 Goodwin Biotechnology Antibody and Recombinant Protein CDMO Product Market Performance
9.7.4 Goodwin Biotechnology Business Overview
9.7.5 Goodwin Biotechnology Recent Developments
9.8 Merck
9.8.1 Merck Antibody and Recombinant Protein CDMO Basic Information
9.8.2 Merck Antibody and Recombinant Protein CDMO Product Overview
9.8.3 Merck Antibody and Recombinant Protein CDMO Product Market Performance
9.8.4 Merck Business Overview
9.8.5 Merck Recent Developments
9.9 Hangzhou Hs-biopharm
9.9.1 Hangzhou Hs-biopharm Antibody and Recombinant Protein CDMO Basic Information
9.9.2 Hangzhou Hs-biopharm Antibody and Recombinant Protein CDMO Product Overview
9.9.3 Hangzhou Hs-biopharm Antibody and Recombinant Protein CDMO Product Market Performance
9.9.4 Hangzhou Hs-biopharm Business Overview
9.9.5 Hangzhou Hs-biopharm Recent Developments
9.10 Wuxibiologics
9.10.1 Wuxibiologics Antibody and Recombinant Protein CDMO Basic Information
9.10.2 Wuxibiologics Antibody and Recombinant Protein CDMO Product Overview
9.10.3 Wuxibiologics Antibody and Recombinant Protein CDMO Product Market Performance
9.10.4 Wuxibiologics Business Overview
9.10.5 Wuxibiologics Recent Developments
9.11 Bioinnobio
9.11.1 Bioinnobio Antibody and Recombinant Protein CDMO Basic Information
9.11.2 Bioinnobio Antibody and Recombinant Protein CDMO Product Overview
9.11.3 Bioinnobio Antibody and Recombinant Protein CDMO Product Market Performance
9.11.4 Bioinnobio Business Overview
9.11.5 Bioinnobio Recent Developments
9.12 Thousand Oaks Biopharmaceuticals
9.12.1 Thousand Oaks Biopharmaceuticals Antibody and Recombinant Protein CDMO Basic Information
9.12.2 Thousand Oaks Biopharmaceuticals Antibody and Recombinant Protein CDMO Product Overview
9.12.3 Thousand Oaks Biopharmaceuticals Antibody and Recombinant Protein CDMO Product Market Performance
9.12.4 Thousand Oaks Biopharmaceuticals Business Overview
9.12.5 Thousand Oaks Biopharmaceuticals Recent Developments
9.13 Cerbios-Pharma SA
9.13.1 Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Basic Information
9.13.2 Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Product Overview
9.13.3 Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Product Market Performance
9.13.4 Cerbios-Pharma SA Business Overview
9.13.5 Cerbios-Pharma SA Recent Developments
9.14 Eurogentec
9.14.1 Eurogentec Antibody and Recombinant Protein CDMO Basic Information
9.14.2 Eurogentec Antibody and Recombinant Protein CDMO Product Overview
9.14.3 Eurogentec Antibody and Recombinant Protein CDMO Product Market Performance
9.14.4 Eurogentec Business Overview
9.14.5 Eurogentec Recent Developments
9.15 HJB
9.15.1 HJB Antibody and Recombinant Protein CDMO Basic Information
9.15.2 HJB Antibody and Recombinant Protein CDMO Product Overview
9.15.3 HJB Antibody and Recombinant Protein CDMO Product Market Performance
9.15.4 HJB Business Overview
9.15.5 HJB Recent Developments
9.16 Bibo Pharma
9.16.1 Bibo Pharma Antibody and Recombinant Protein CDMO Basic Information
9.16.2 Bibo Pharma Antibody and Recombinant Protein CDMO Product Overview
9.16.3 Bibo Pharma Antibody and Recombinant Protein CDMO Product Market Performance
9.16.4 Bibo Pharma Business Overview
9.16.5 Bibo Pharma Recent Developments
9.17 MabPlex International
9.17.1 MabPlex International Antibody and Recombinant Protein CDMO Basic Information
9.17.2 MabPlex International Antibody and Recombinant Protein CDMO Product Overview
9.17.3 MabPlex International Antibody and Recombinant Protein CDMO Product Market Performance
9.17.4 MabPlex International Business Overview
9.17.5 MabPlex International Recent Developments
9.18 Genscriptprobio
9.18.1 Genscriptprobio Antibody and Recombinant Protein CDMO Basic Information
9.18.2 Genscriptprobio Antibody and Recombinant Protein CDMO Product Overview
9.18.3 Genscriptprobio Antibody and Recombinant Protein CDMO Product Market Performance
9.18.4 Genscriptprobio Business Overview
9.18.5 Genscriptprobio Recent Developments
9.19 Vetter
9.19.1 Vetter Antibody and Recombinant Protein CDMO Basic Information
9.19.2 Vetter Antibody and Recombinant Protein CDMO Product Overview
9.19.3 Vetter Antibody and Recombinant Protein CDMO Product Market Performance
9.19.4 Vetter Business Overview
9.19.5 Vetter Recent Developments
9.20 Etinpro (Beijing) Co
9.20.1 Etinpro (Beijing) Co Antibody and Recombinant Protein CDMO Basic Information
9.20.2 Etinpro (Beijing) Co Antibody and Recombinant Protein CDMO Product Overview
9.20.3 Etinpro (Beijing) Co Antibody and Recombinant Protein CDMO Product Market Performance
9.20.4 Etinpro (Beijing) Co Business Overview
9.20.5 Etinpro (Beijing) Co Recent Developments
9.21 Boehringer Ingelheim BioXcellence
9.21.1 Boehringer Ingelheim BioXcellence Antibody and Recombinant Protein CDMO Basic Information
9.21.2 Boehringer Ingelheim BioXcellence Antibody and Recombinant Protein CDMO Product Overview
9.21.3 Boehringer Ingelheim BioXcellence Antibody and Recombinant Protein CDMO Product Market Performance
9.21.4 Boehringer Ingelheim BioXcellence Business Overview
9.21.5 Boehringer Ingelheim BioXcellence Recent Developments
9.22 Lonza
9.22.1 Lonza Antibody and Recombinant Protein CDMO Basic Information
9.22.2 Lonza Antibody and Recombinant Protein CDMO Product Overview
9.22.3 Lonza Antibody and Recombinant Protein CDMO Product Market Performance
9.22.4 Lonza Business Overview
9.22.5 Lonza Recent Developments
9.23 3SBio Inc
9.23.1 3SBio Inc Antibody and Recombinant Protein CDMO Basic Information
9.23.2 3SBio Inc Antibody and Recombinant Protein CDMO Product Overview
9.23.3 3SBio Inc Antibody and Recombinant Protein CDMO Product Market Performance
9.23.4 3SBio Inc Business Overview
9.23.5 3SBio Inc Recent Developments
9.24 Porton
9.24.1 Porton Antibody and Recombinant Protein CDMO Basic Information
9.24.2 Porton Antibody and Recombinant Protein CDMO Product Overview
9.24.3 Porton Antibody and Recombinant Protein CDMO Product Market Performance
9.24.4 Porton Business Overview
9.24.5 Porton Recent Developments
10 Antibody and Recombinant Protein CDMO Market Forecast by Region
10.1 Global Antibody and Recombinant Protein CDMO Market Size Forecast
10.2 Global Antibody and Recombinant Protein CDMO Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Antibody and Recombinant Protein CDMO Market Size Forecast by Country
10.2.3 Asia Pacific Antibody and Recombinant Protein CDMO Market Size Forecast by Region
10.2.4 South America Antibody and Recombinant Protein CDMO Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Antibody and Recombinant Protein CDMO by Country
11 Forecast Market by Type and by Application (2024-2029)
11.1 Global Antibody and Recombinant Protein CDMO Market Forecast by Type (2024-2029)
11.1.1 Global Forecasted Sales of Antibody and Recombinant Protein CDMO by Type (2024-2029)
11.1.2 Global Antibody and Recombinant Protein CDMO Market Size Forecast by Type (2024-2029)
11.1.3 Global Forecasted Price of Antibody and Recombinant Protein CDMO by Type (2024-2029)
11.2 Global Antibody and Recombinant Protein CDMO Market Forecast by Application (2024-2029)
11.2.1 Global Antibody and Recombinant Protein CDMO Sales (K Units) Forecast by Application
11.2.2 Global Antibody and Recombinant Protein CDMO Market Size (M USD) Forecast by Application (2024-2029)
12 Conclusion and Key Findings
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
